IRVINE, Calif., June 24 Stason Pharmaceuticals, Inc., avertically integrated cGMP contract development organization announced todaythat it has appointed Diana Wood as Vice President, Business Development. Ms.Wood will be responsible for all business development functions, includingguiding Stason's global business development activities. Ms. Wood is a seniorexecutive with extensive experience in sales, marketing, business andstrategic planning, product development and general management on a worldwidebasis. She will report directly to Chief Executive Officer Harry T. Fan. Mostrecently, Diana Wood served as the Executive Vice President, BusinessDevelopment at Chiltern International, Inc., where she oversaw the company'sglobal business development and marketing functions, and advised clients ontheir product development platforms. Prior to joining Chiltern International,Ms. Wood served as the Director, Product Development for Oncology at ChugaiPharma USA in San Diego.
"We are pleased to welcome Diana to Stason," said Mr. Fan. "As a seasonedbusiness development executive, she has built a highly respected track recordand earned the trust of the pharmaceutical community. Diana will be astrategically important asset to our company. Furthermore, by bringing anextensive knowledge of the pharmaceutical industry and its regulatoryenvironment combined with confidence and multifaceted business experience, shewill continue to broaden and strengthen our relationship with our drugdevelopment partners."
"I am delighted to join Stason, a fast-growing and forward thinkingorganization," Ms. Wood said. "Today's product development landscape ischanging rapidly and paradigms are shifting towards a more technologicallydriven development process from the bench to market. Stason embraced thesechanges early on, reducing overall development time and costs. I look forwardto bringing new opportunities to Stason and to further expand our globalgrowth."
About Stason Pharmaceuticals:
Founded in 1994, Stason Pharmaceuticals, Inc. has evolved into avertically integrated cGMP contract development organization with affiliatesand locations in Texas, Massachusetts, Japan, China and Taiwan that providecomplete turn-key drug development solutions for API, prototype and finalproduct, clinical supplies for all phases, and commercial production anddistribution. Stason also out-licenses internally developed technologies tocompanies worldwide. Stason is specialized in developing and processinghigh-potency products, including oncology drugs.
SOURCE Stason Pharmaceuticals, Inc.